SCHEMBL3975262

SCHEMBL3975262

CCc1ccccc1-n1nc(C(C)(C)C)cc1Nc1ncccc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 10/20 0.47
MAPK13 O15264 9/20 0.47
MAPK12 P53778 9/20 0.47
MAPK11 Q15759 9/20 0.47
DHODH Q02127 3/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
HTT P42858 2/20 0.46
LMNA P02545 3/20 0.44
GAA P10253 1/20 0.44
GRN P28799 1/20 0.44
SORT1 Q99523 1/20 0.44
PKM P14618 2/20 0.43
GMNN O75496 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TTR P02766 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
NFKB1 P19838 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3982024 0.92 MAPK13 (0.48) MAPK14MAPK13MAPK12MAPK11DHODH
SCHEMBL4251789 0.89 DHODH (0.48) MAPK14MAPK13MAPK12MAPK11DHODH
SCHEMBL3976255 0.87 MAPK13 (0.45) MAPK14MAPK13MAPK12MAPK11DHODH
SCHEMBL5007743 0.85 CLCN2 (0.51) MAPK14MAPK13MAPK12MAPK11GRN
SCHEMBL3979286 0.84 LMNA (0.51) MAPK14MAPK13MAPK12MAPK11DHODH
SCHEMBL3974739 0.84 MAPK14 (0.48) MAPK14MAPK13MAPK12MAPK11DHODH
SCHEMBL3978605 0.84 DHODH (0.46) MAPK14MAPK13MAPK12MAPK11DHODH
SCHEMBL27654182 0.83 DHODH (0.44) MAPK14MAPK13MAPK12MAPK11DHODH
SCHEMBL3976410 0.83 LMNA (0.47) MAPK14MAPK13MAPK12MAPK11DHODH
SCHEMBL3973612 0.82 LMNA (0.50) MAPK14MAPK13MAPK12MAPK11DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes GPR119, GOT2, IAPP MAPK14 2768/4885MAPK13 1918/4885MAPK12 2241/4885
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES GPR119, GOT2, IAPP MAPK14 2768/4885MAPK13 1918/4885MAPK12 2241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.